학술논문

Prognostic value of CD45 transcriptional expression in head and neck cancer.
Document Type
Article
Source
European Archives of Oto-Rhino-Laryngology. Jan2018, Vol. 275 Issue 1, p225-232. 8p.
Subject
*HEAD & neck cancer
*CD45 antigen
*GENETIC transcription
*SQUAMOUS cell carcinoma
*LYMPHOCYTES
*PROGRESSION-free survival
*IMMUNOHISTOCHEMISTRY
*PROGNOSIS
Language
ISSN
0937-4477
Abstract
Introduction: Tumor-infiltrating lymphocytes (TILs) have a recognized antitumor activity in head and neck squamous cell carcinoma (HNSCC). CD45 is one of the most highly expressed proteins in lymphocytes. We carry out a study to assess the prognostic value of transcriptional expression of CD45 in HNSCC. Material and methods: We determined the transcriptional expression of CD45 in 160 consecutive HNSCC patients and compared the TIL values according to the CD45 expression. Results: Five-year disease-free survival for patients with a high transcriptional expression of CD45 ( n = 107) was 62.4% and for patients with a low expression ( n = 53) it was 36.2% ( P = 0.003). Patients with a high expression of CD45 had a better local recurrence-free survival and disease-specific survival. The results of a multivariate analysis showed that patients with a low expression of CD45 had 2.0-fold high risk of recurrence (95% CI 1.2-3.2, P = 0.003). In oropharyngeal carcinomas, HPV-positive tumors showed a higher transcriptional CD45 expression than HPV-negative tumors. Tumors with high CD45 expression had immunohistochemical TIL scores significantly higher than those with low CD45 expression. Conclusion: According to our results, CD45 expression is a potential marker for tumor outcome in HNSCC patients. [ABSTRACT FROM AUTHOR]